The EWS/FLI-1 fusion gene, resulting from a t(11;22) translocation, plays a key role in the pathogenesis of Ewing's sarcoma. Previously, we have shown that antisense oligonucleotides designed against EWS-Fli-1 inhibited tumour growth in nude mice provided they were delivered intratumorally by nanocapsules or by CTAB-coated nanospheres. In this study, we have used two types of nanospheres (designated as type 1 and type 2 nanospheres) stabilized with chitosan for both intratumoural and systemic administration of oligonucleotides.
INTRODUCTION
The Ewing sarcoma is a metastatic bone cancer of children and young adults. At the cellular level poorly differentiated round cells characterize it; a genetic abnormality is associated with this malignancy, which consists in a rearrangement of chromosomes 22 and 11: t(11;22)(q24;q12). When such translocation occurs, the 5' part of the transcriptional activator EWS -located on chromosome 22 -fuses with the 3' part of the transcription factor Fli-1 -originating from chromosome 11 -which allows the appearance of a new EWS-Fli-1chimeric
gene. This translocation, characterized by four different junction points (1, 2, 3 and 4) is present in 90 % of cases of Ewing sarcoma 1 . Junction point 1 is the most frequent (50%) 1 . It has been shown that the EWS-Fli-1 gene might act as a transforming gene when transfected into murine fibroblasts 2 . In addition, inhibition of EWS-Fli-1 in human SK-N-MC cells results in inhibition of growth 3 .
Thus, EWS-Fli-1 gene may be considered as a relevant target for therapeutic agents towards
Ewing sarcoma since it is expressed in 90 % of Ewing sarcomas. In this view, inhibition of EWS-Fli-1, junction point 1, has been tried by ourselves and by others using antisense oligonucleotides (AS-ONs) in cell culture and in vivo. 
RESULTS

Nanospheres characterization and oligonucleotides loading
Type 1 nanospheres and types 2 nanospheres loaded with oligonucleotides had sizes of 139 nm (± 47 nm) and 65 nm (± 17 nm), respectively and their zeta potentials were positive (+ 16.5 mV and + 21 mV, respectively). ON binding varied greatly according to the nature of the nanospheres. As shown in Figure 1A , ON loading was much more efficient with type 2 nanospheres than with either type 1 or CTAB-coated nanospheres. Indeed, for an ON concentration of 100 µM, the yield of association was still above 80% with type 2 nanospheres whereas it accounted only for few percents in case of type 1 or CTAB coated nanospheres ( Fig 1A) .
Stability of AS-ONs in the cells and biological medium
Type 1 and 2 chitosan nanospheres as well as CTAB-overcoated nanospheres significantly improved AS-ON stability in DMEM containing 10% heat-inactivated newborn calf serum ( Fig 1B) . However, type 2 nanospheres offered much better protection than the other types of nanospheres. After 24 h incubation, more than 80 % ONs were, indeed, kept undegraded with type 2 chitosan nanospheres whereas less than 25 % intact ONs were recovered with the other types of nanospheres.
Cell culture
The efficacy of the AS-ON targeted against the fusion oncogene EWS-Fli-1 was investigated in NIH/3T3 EWS-Fli-1 cells by measuring cell growth, protein expression as well as the mRNA level by Northern blot in comparison to a control oligonucleotide.
When using the cationic lipid Cytofectin as transfection agent to deliver ONs into the cells, significant EWS-Fli-1 inhibition occurred as measured both by Western and Northern blot (Fig 2A) . Cytofectin is known to generally deliver oligonucleotides in the cell nucleus. After incubation of the antisense ON associated as a complex with Cytofectine, a greater growth inhibition was observed in NIH/3T3 EWS-Fli-1 cells. (Fig 2B) than when using the control 6 ON. When using type 2 chitosan nanospheres (with 5 kDa chitosan) as a delivery agent, no effect was observed neither on the cell growth nor on the EWS-Fli-1 expression (Fig 2A and   2B ). With type 1 chitosan nanospheres, no growth inhibition was detected too, but inhibition of EWS-Fli-1 was found to take place at the level of mRNA as indicated by Northern Blot.
However, it was not specific because the same effect was also obtained with the control ON loaded onto type 1 chitosan nanospheres (data not shown). Thus, on the contrary to Cytofectine, type 1 and type 2 chitosan nanospheres were unable to trigger an antisense effect on the EWS-Fli-1 targeted sequence.
Cellular uptake was investigated with AS-ON labelled in 3' and 5' position by fluoresceine.
Cell distribution observed by confocal microscopy showed that nanospheres induced an important cell internalization of the ON which were found in the cell cytoplasm in a punctuate manner, corresponding to endocytic vesicles (Fig 3) .
Inhibition of tumor growth in nude mice
The effect of AS-ON (5' GTA-GCG-AAG-GGTs-TsCsTs-GsCsTs-GsCC-CGT-AGC-TGC- We also tested the efficiency of the chitosan nanospheres by systemic injection. When complexed with the antisense oligonucleotide type 2 chitosan nanospheres repeatedly displayed an antitumoural activity (Fig 4B) . The lack of effect of the control ON either alone or loaded onto type 2 nanospheres needs to be confirmed. It seems that salt concentration in the injection might play a role. This has also to be investigated. AS-ONs loaded onto type 1 nanospheres had no effect by systemic injection (Fig 4B) .
Rem: Animals were housed and handled according to the recommended guidelines 5 . They were humanely sacrificed by CO 2 inhalation.
Effect of an AS-ON containing methylated CpGs
In order to still enhance the inhibition of the tumour growth, both antisense and control ONs context of these CpG is not favourable for such an effect 6 . After loading these ONs onto type 2 chitosan nanospheres and after intratumoural injection, complete regression of tumour growth was observed with the methylated AS-ON, whereas all the controls failed to cure the animals [ Fig 5] . This shows that imunostimulation was not responsible for the observed tumour growth inhibition.
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DISCUSSION
We initially reported that phosphorothioate antisense oligonucleotides significantly inhibited, although not completely, an EWS-Fli-1 dependant tumour in nude mice when these oligomers were encapsulated into poly-isobutylcyanoacrylate nanocapsules and injected intratumorally 7 .
A similar observation was done by using a structured chimeric phosphodiester/phosphorothioate antisense oligonucleotide adsorbed onto CTAB-overcoated poly-isobutylcyanoacrylate nanospheres 4 . This was rather unexpected since no effect had been obtained with theses antisense nanospheres on the same cells in culture and since the two antisense oligonucleotides used with either nanospheres or nanocapsules were different 4 . In view of the toxicity of CTAB and of the easier preparation of nanospheres compared to nanocapsules and in order to still improve ON delivery in experimental Ewing sarcoma, we have developed a new strategy with the replacement of CTAB by chitosan which is likely a less toxic compound also able to bind ON.
For this purpose we have, in a first time, added the chitosan at the end of the polymerisation time to obtain the type 1 nanosphere where chitozan was just adsorbed on the nanosphere particle. They are able to bind twice more ON than CTAB nanosphere (Fig 1A) , with an equivalent ON protection toward nuclease degradation (Fig 1B) . In a second time we have developed a copolymerisation method. Since the polymerisation of the monomer proceeds in the presence of chitosan, this cationic polysaccharide becomes probably covalently bound to the cyanoacrylate polymer, forming a multiblock copolymer. Indeed, compounds such as amines, amino acids or tertiary bases such as phosphine and pyridine have been shown to initiate the polymerization through a zwitterionic mechanism 8 . Type 2 chitosan nanospheres has, indeed, led to a much more efficient loading of ON than type 1 chitosan nanospheres, 9 with a much better protection against degradation in a biological medium (shown in fig 1 A   and fig 1B) . We believe that ON and chitosan, which are strongly bound together by ion pairing, may desorb from the type 1 nanospheres surface whereas this removal is greatly reduced in type 2 nanospheres due to the covalent binding of chitosan to the poly-isohexylylcyanoacrylate core. Then, ON were better protected when associated with type 2 nanospheres since degradation likely took place only when the ON molecules were released.
These two points, binding and resistance to degradation, seem essential for the optimal in vivo delivery of ONs.
These chitosan-based nanotechnologies displayed rather similar tumour inhibition in mice by intratumoural injection (Fig 4A) , showing, on the other hand, no specific activity in vitro in cell culture (Fig 2) . The lack of efficiency was probably not due to the inability of the type 2
nanosphere to cross the cell membrane, because by confocal microscopy we have observed an intracellular fluorescence in vesicular structures (fig 3) . This means probably that ON was We, thus, propose that there is an intrinsic sensitivity of this tumour to the EWS-Fli-1 targeted AS-ONs, when these molecules are delivered by means of systems containing cyanoacrylate polymers. Indeed, previous assays performed with the same AS-ON but as a complex with dendrimers failed in inhibiting the tumour growth on the same nude mice model 11 . When using cationic lipids instead of dendrimers we observed a toxic effect which is not compatible with an efficient treatment (results not shown).
Thanks to this technology, we have obtained repeatedly in preliminary experiments an increased antitumor activity after systemic injection of AS-ON bound to type 2 nanospheres (Fig 4B) . This effect did not occur when chitosan was only reversibly bound to the type 1 nanospheres (Fig 4B) or with nanospheres alone. This exciting result was promising for further application of AS-ON bound to type 2 nanospheres. It is known that alongside their antisense effect some CpG containing oligonucleotides inhibit tumour growth by immunostimulation 12 . This effect is suppressed when the CpG involved are methylated on the Cs. Noteworthy, it was observed that when associated with type 2 chitosan nanospheres, the AS-ON with two CpG tracts methylated has led to a complete tumour regression, which has never been obtained before ( fig 5) . In addition, a mouse immunostimulating oligonucleotide had no effect on the tumour growth. These results argue for a real antisense effect in vivo and also show the potency that can be reached by combining well-designed delivery vectors together with rational ON modifications. 
